文献速递妇科产科

抗生素对复发性妇科肿瘤免疫治疗应答的影响

Impact of antibiotic treatment on immunotherapy response in women with recurrent gynecologic cancer.
PubMed 文献 · Gynecol Oncol · 2021-01-24

该回顾性队列纳入101例接受免疫检查点抑制剂(ICI)治疗的复发性子宫内膜癌、宫颈癌和卵巢癌女性,评估抗生素(ABX)对免疫治疗应答的影响。结果显示,ICI前30天内使用ABX(pABX)与应答率降低、无进展生存期(PFS)和总生存期(OS)缩短相关,而同期使用ABX(cABX)未见显著影响。

要点

  • ICI前30天内使用抗生素与更差应答率、PFS和OS独立相关。
  • 同期使用抗生素未显著影响PFS或OS。
  • 需进一步研究妇科肿瘤ICI应答的预测因素。

核心结论

  • 在复发性子宫内膜癌、卵巢癌和宫颈癌接受ICI的女性中,pABX而非cABX与应答率降低、PFS和OS缩短相关。

主要发现

  • 任何ABX vs 无ABX的ICI应答率无差异(p=0.89),cABX vs 无ABX亦无差异(p=0.33)。
  • pABX vs 无ABX的应答率降低:部分缓解8.7% vs 30.8%,完全缓解4.3% vs 9.0%,p=0.002。
  • 单因素分析中,pABX与更差PFS相关(2.9 vs 8.9个月;HR 2.53,95% CI 1.48-4.31,p<0.001)和OS相关(9.3 vs 19.9个月;HR 2.29,95% CI 1.22-4.32,p=0.01)。
  • cABX未显著影响PFS(9.3 vs 6.0个月;HR 0.70,95% CI 0.43-1.12;p=0.14)或OS(13.4 vs 16.3个月;HR 0.89,95% CI 0.51-1.54;p=0.68)。
  • 多因素分析中,pABX与显著降低的PFS(HR 3.10,95% CI 1.75-5.49,p<0.001)和OS(HR 3.03,95% CI 1.50-6.10,p=0.002)相关。

临床怎么用

  • 对计划接受ICI的复发性妇科肿瘤患者,应审慎评估ICI前30天内抗生素使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE(S): To identify whether antibiotics (ABX) impact immunotherapy (ICI) response rate (RR), progression-free survival (PFS), and overall survival (OS) in women with recurrent endometrial (EC), cervical (CC) and ovarian cancer (OC). METHODS: This retrospective cohort study included women with recurrent EC, CC, and OC treated with ICIs from 1/1/17-9/1/2020. ABX were defined as 30 days before (pABX) or concurrently (cABX) with ICI. The impact of ABX upon PFS and OS was assessed by univariate analysis and multivariable Cox regression. RESULTS: Of 101 women, 52.5% (n = 53) had recurrent EC, 21.4% (n = 22) CC and 25.7% (n = 26) OC. 56.9% (n = 58) received ABX, with 22.8% (n = 23) pABX and 46.5% (n = 47) cABX. While no difference was observed in ICI RR for any ABX vs. none (p = 0.89) and cABX vs. none (p = 0.33), pABX (n = 23) were associated with decreased RR vs. none (n = 78) (Partial Response - 8.7% vs. 30.8%; Complete Response - 4.3% vs. 9.0%; p = 0.002). On univariate analysis, pABX were associated with worsened PFS (2.9 vs. 8.9 months; HR 2.53, 95% CI 1.48-4.31, p < 0.001) and OS (9.3 vs. 19.9 months; HR 2.29, 95% CI 1.22-4.32, p = 0.01). No PFS or OS difference was noted for cABX (PFS - 9.3 vs. 6.0 months; HR 0.70, 95% CI 0.43-1.12; p = 0.14; OS - 13.4 vs. 16.3 months; HR 0.89, 95% CI 0.51-1.54; p = 0.68). On multivariable analysis, pABX were associated with significantly decreased PFS (HR 3.10, 95% CI 1.75-5.49, p < 0.001) and OS (HR 3.03, 95% CI 1.50-6.10, p = 0.002). CONCLUSIONS: In women with recurrent EC, OC, and CC receiving ICI, pABX, but not cABX, are associated with decreased RR, PFS, and OS. Further investigation is warranted to understand predictors of ICI response in women with gynecologic cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Chambers LM, Michener CM, Rose PG, et al. Impact of antibiotic treatment on immunotherapy response in women with recurrent gynecologic cancer. Gynecol Oncol. 2021. PMID: 33504455. doi:10.1016/j.ygyno.2021.01.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。